Appropriate endpoints for renal transplantation clinical trials

Claudio Ponticelli, Mariarosaria Campise

Research output: Contribution to journalArticle

Abstract

The patient and graft survival are the primary endpoints to evaluate safety and efficacy of the immunosuppressive treatments in renal transplantation. Today, however, the results are so good that a huge number of patients is needed to find statistically significant differences between treatments. Secondary endpoints are, therefore, used. Infections and other side effects are good endpoints for safety. Acute rejection is the best surrogate endpoint for efficacy. The diagnosis of acute rejection rests on an increase of plasma creatinine but how much the increase should be to define rejection is still unclear. Moreover, a number of noninvasive techniques can be used to exclude causes of graft dysfunction other than rejection. Thus, renal biopsy may be required to confirm the diagnosis. The severity of acute rejection may be used as a tertiary endpoint, but the criteria for assessing the severity of rejection still need to be standardized either based on clinical or histological variables.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalDrug Information Journal
Volume31
Issue number1
Publication statusPublished - 1997

Fingerprint

Transplantation (surgical)
Grafts
Kidney Transplantation
Clinical Trials
Safety
Biopsy
Graft Survival
Immunosuppressive Agents
Creatinine
Biomarkers
Transplants
Kidney
Plasmas
Infection
Therapeutics

Keywords

  • Efficacy
  • Endpoint
  • Rejection
  • Safety
  • Surrogate endpoints
  • Transplantation

ASJC Scopus subject areas

  • Health Informatics
  • Public Health, Environmental and Occupational Health
  • Nursing(all)
  • Pharmacology

Cite this

Ponticelli, C., & Campise, M. (1997). Appropriate endpoints for renal transplantation clinical trials. Drug Information Journal, 31(1), 207-212.

Appropriate endpoints for renal transplantation clinical trials. / Ponticelli, Claudio; Campise, Mariarosaria.

In: Drug Information Journal, Vol. 31, No. 1, 1997, p. 207-212.

Research output: Contribution to journalArticle

Ponticelli, C & Campise, M 1997, 'Appropriate endpoints for renal transplantation clinical trials', Drug Information Journal, vol. 31, no. 1, pp. 207-212.
Ponticelli, Claudio ; Campise, Mariarosaria. / Appropriate endpoints for renal transplantation clinical trials. In: Drug Information Journal. 1997 ; Vol. 31, No. 1. pp. 207-212.
@article{68d326d65064412dbdc52ff1cc488f66,
title = "Appropriate endpoints for renal transplantation clinical trials",
abstract = "The patient and graft survival are the primary endpoints to evaluate safety and efficacy of the immunosuppressive treatments in renal transplantation. Today, however, the results are so good that a huge number of patients is needed to find statistically significant differences between treatments. Secondary endpoints are, therefore, used. Infections and other side effects are good endpoints for safety. Acute rejection is the best surrogate endpoint for efficacy. The diagnosis of acute rejection rests on an increase of plasma creatinine but how much the increase should be to define rejection is still unclear. Moreover, a number of noninvasive techniques can be used to exclude causes of graft dysfunction other than rejection. Thus, renal biopsy may be required to confirm the diagnosis. The severity of acute rejection may be used as a tertiary endpoint, but the criteria for assessing the severity of rejection still need to be standardized either based on clinical or histological variables.",
keywords = "Efficacy, Endpoint, Rejection, Safety, Surrogate endpoints, Transplantation",
author = "Claudio Ponticelli and Mariarosaria Campise",
year = "1997",
language = "English",
volume = "31",
pages = "207--212",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "1",

}

TY - JOUR

T1 - Appropriate endpoints for renal transplantation clinical trials

AU - Ponticelli, Claudio

AU - Campise, Mariarosaria

PY - 1997

Y1 - 1997

N2 - The patient and graft survival are the primary endpoints to evaluate safety and efficacy of the immunosuppressive treatments in renal transplantation. Today, however, the results are so good that a huge number of patients is needed to find statistically significant differences between treatments. Secondary endpoints are, therefore, used. Infections and other side effects are good endpoints for safety. Acute rejection is the best surrogate endpoint for efficacy. The diagnosis of acute rejection rests on an increase of plasma creatinine but how much the increase should be to define rejection is still unclear. Moreover, a number of noninvasive techniques can be used to exclude causes of graft dysfunction other than rejection. Thus, renal biopsy may be required to confirm the diagnosis. The severity of acute rejection may be used as a tertiary endpoint, but the criteria for assessing the severity of rejection still need to be standardized either based on clinical or histological variables.

AB - The patient and graft survival are the primary endpoints to evaluate safety and efficacy of the immunosuppressive treatments in renal transplantation. Today, however, the results are so good that a huge number of patients is needed to find statistically significant differences between treatments. Secondary endpoints are, therefore, used. Infections and other side effects are good endpoints for safety. Acute rejection is the best surrogate endpoint for efficacy. The diagnosis of acute rejection rests on an increase of plasma creatinine but how much the increase should be to define rejection is still unclear. Moreover, a number of noninvasive techniques can be used to exclude causes of graft dysfunction other than rejection. Thus, renal biopsy may be required to confirm the diagnosis. The severity of acute rejection may be used as a tertiary endpoint, but the criteria for assessing the severity of rejection still need to be standardized either based on clinical or histological variables.

KW - Efficacy

KW - Endpoint

KW - Rejection

KW - Safety

KW - Surrogate endpoints

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031053469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031053469&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 207

EP - 212

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 1

ER -